Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7123972 | 0.98 | LTA4H (0.49) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10429856 | 0.86 | ADRA2A (0.43) | LTA4HCYP1A2CYP2C9CYP2C19HTT | |
| Hydrochloric Acid SCHEMBL15412521 | 0.84 | ADRA2A (0.42) | LTA4HHTTBCHEL3MBTL1LMNA | |
| SCHEMBL11687298 | 0.84 | LTA4H (0.48) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9706129 | 0.84 | ALDH1A3 (0.39) | CYP1A2CYP2C9CYP2C19BCHE | |
| SCHEMBL11682289 | 0.81 | BCHE (0.49) | CYP1A2CYP2D6CYP2C9CYP2C19PPARG | |
| SCHEMBL11675661 | 0.79 | LTA4H (0.49) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17807116 | 0.78 | LTA4H (0.61) | LTA4HPPARGPPARAL3MBTL1CNR2 | |
| SCHEMBL5684114 | 0.77 | LTA4H (0.65) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15571018 | 0.77 | KDM4E (0.43) | CYP1A2CYP2C9CYP2C19HTTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20040220281-A1 | Treatment of hormone-refractory prostate cancer | MANITOBA, UNIVERSITY OF (CA) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | LTA4H 2819/4885CYP1A2 1354/4885CYP2D6 2032/4885 |
| US-20040220281-A1 | Treatment of hormone-refractory prostate cancer | KLK3, ACP3, AR | LTA4H 3204/4885CYP1A2 1327/4885CYP2D6 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.